$135.08▴ 0.00%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
✦ The read
Apogee Therapeutics, Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Why Wall Street Can't Get Enough of This Dividend King
3 Reasons to Buy AbbVie Stock Like There's No TomorrowHalper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders
What This Apogee Insider Move Might Mean After a 247% Stock Run
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty